Efficacy of octreotide in the management of chronic diarrhoea in AIDS

Joan Romeu, Josep M. Miró, Guillem Sirera, Josep Mallolas, Joan Arnal, M. Eugenia Valls, Frederic Tortosa, Bonaventura Clotet, Màrius Foz

Research output: Contribution to journalArticleResearchpeer-review

40 Citations (Scopus)


Patients with HIV infection were studied to assess the efficacy of octreotide, a somatostatin analogue, in the long-term management of refractory diarrhoea. Dosage of subcutaneous octreotide was increased progressively at 48 h intervals from 150 to 300, 750 and 1500 μg/day according to response. Twenty-nine patients, 21 with Cryptosporidium enteritis, one with Isospora belli enteritis and seven with no identifiable pathogen were selected for the study; four of these were excluded from the study because of death during the first month (two cases), abdominal pain and acute pancreatitis (one case each). Twenty-five patients were evaluable for response. Ten patients (four with Cryptosporidium enteritis, five without an identifiable pathogen and one with I. belli enteritis) achieved a complete response (40%) and nine cases (all with cryptosporidial enteritis) had a partial response (36%). Patients with higher weight and Karnofsky performance status and non-cryptosporidial enteritis had a better response to treatment. Mean durations of treatment and response were 4.2 ± 4.2 and 4.4 ± 4.5 months, respectively. In the absence of specific agents for cryptosporidial enteritis and HIV enteropathy, octreotide was found to be useful in the management of chronic diarrhoea in AIDS patients.
Original languageEnglish
Pages (from-to)1495-1499
Issue number12
Publication statusPublished - 1 Jan 1991


  • Chronic diarrhoea
  • Cryptosporidium
  • HIV enteropathy
  • Octreotide


Dive into the research topics of 'Efficacy of octreotide in the management of chronic diarrhoea in AIDS'. Together they form a unique fingerprint.

Cite this